Join UNITY's medical leaders and colleagues from accross Northern California for an exclusive peer-to-peer presentation on UNITY's latest advancements and what they mean for your patients and your practice.

Session Overview

Prenatal screening should be simple. With a single maternal blood draw as early as 9 weeks, UNITY Complete delivers pregnancy-specific fetal risk assessment for aneuploidies, recessive conditions, and fetal antigen status through one streamlined workflow.

As leaders in cfDNA screening for recessive conditions, UNITY was first to assess fetal risk without requiring partner testing and now offers the first-and-only fetal antigen NIPT available in the US for red blood cell and platelet antigens. Together, these advancements enable more results for more patients from a single test and support informed care earlier in pregnancy.

What you'll learn

• Explore the full suite of screening options available with UNITY Complete, including the first-and-only fetal antigen NIPT in the U.S. for red blood cell and platelet antigens.
• Understand the technology behind UNITY, including our patented QCT™ platform, and how it enables pregnancy-specific fetal risk assessment from a single maternal blood draw.
• See how UNITY streamlines workflow by eliminating the need for partner testing while delivering more actionable results, earlier in pregnancy.
• Review real-world clinical applications and case examples to understand how UNITY results can inform management decisions and support patient counseling.